Navigation Links
Promising Results in Treating Facial Bruising From Injectables

Top physician leading clinical trials

FREEPORT, N.Y., Sept. 26 /PRNewswire/ -- Physicians nationwide report promising results in treating facial bruising from injectable cosmetic treatments by using Pinoxide(TM), an active ingredient best known for treating under-eye circles.

Pinoxide is a proprietary blend of bicyclic monoterpene dials (BMTd) created by AGI Dermatics and formulated in the company's Remergent Microcirculation Therapy product. Pinoxide has been clinically proven to speed blood flow, warm the skin, increase resistance to cold, and reduce dark under- eye symptoms. Additional research suggests Pinoxide may also contribute to promoting firmness and resiliency in the skin. Now, physicians are studying the ingredient's ability to heal bruising.

Dr. Mark G. Rubin, a board-certified dermatologist currently practicing at the Lasky Clinic in Beverly Hills, is conducting the clinical trials on Pinoxide, applying the Microcirculation Therapy formula to the injection site immediately after use of skin fillers such as collagen, Restylane and Juvederm, or Botox.

"Anatomically speaking, dark circles are like bruises - so the science behind using Pinoxide for bruising makes total sense," said Dr. Rubin. "The skin discoloration during bruising is the result of blood leaking from damaged blood vessels and surfacing to the skin. Similarly, blood vessels under the eyes can burst, leading to the appearance of unattractive dark circles."

Leading dermatologists share Dr. Rubin's opinion. Dr. Thomas Francel, a board certified plastic surgeon, has found that application of MicroCirculation Therapy on his patients reduces the appearance of skin bruising, and decreases the amount of healing time for the bruise. Dr. Francel is the Chief of Plastic Surgery at St. John's Mercy Medical Center and an Associate Professor of Surgery at St. Louis University.

Injectable cosmetic treatments are among the five top most requested aesthetic treatments nationwide last year. According to the American Society for Aesthetic Plastic Surgery, more than 5 million women had injectable cosmetic treatments last year. Bruising is a common temporary side effect.

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals.

SOURCE AGI Dermatics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):